Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Inventory (2022 - 2025)

Historic Change in Inventory for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $5.9 million.

  • Arcutis Biotherapeutics' Change in Inventory rose 106415.71% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 127841.61%. This contributed to the annual value of $400000.0 for FY2024, which is 9288.26% down from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Change in Inventory is $5.9 million, which was up 106415.71% from -$518000.0 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Change in Inventory registered a high of $5.9 million during Q3 2025, and its lowest value of -$779000.0 during Q4 2023.
  • Its 4-year average for Change in Inventory is $1.6 million, with a median of $1.0 million in 2023.
  • Data for Arcutis Biotherapeutics' Change in Inventory shows a peak YoY increase of 162654.87% (in 2025) and a maximum YoY decrease of 18183.25% (in 2025) over the last 5 years.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' Change in Inventory stood at $3.2 million in 2022, then crashed by 124.29% to -$779000.0 in 2023, then soared by 134.02% to $265000.0 in 2024, then soared by 2123.02% to $5.9 million in 2025.
  • Its Change in Inventory stands at $5.9 million for Q3 2025, versus -$518000.0 for Q2 2025 and $2.0 million for Q1 2025.